Pharmaceutical Weight Loss Powder CAS 282526-98-1 Cetilistat

Production Introduction:

Cetilistat was approved in September 2013 by the Japanese Ministry of Health, Labor and Welfare for the treatment of obesity, limited to patients with both type 2 diabetes mellitus (T2DM) and dyslipidemia, and with a body mass index (BMI)25 kg/m2 in spite of dietary treatment and/or exercise therapy. As with orlistat, cetilistat works via inhibition of pancreatic lipases in the gut to inhibit fat absorption and thereby reduce caloric uptake from diet. The medicinal chemistry program has not been described in the scientific literature, but the patent describing cetilistat also describes the synthesis of analogs with varied aryl substituents and lipophilic tails.

Application:
 

Cetilistat is a weight loss drug used in combination with a low calorie diet. It works by blocking a substantial amount of fat from being digested and absorbed into the body. This medicine is classified as a lipase inhibitor and it works directly on the digestive system where it blocks the action of a lipolytic enzyme called lipase. These lipases are what the body uses to digest the fat.